DALLAS — Results presented here showed the use of some NSAIDs after primary total hip arthroplasty may not increase the risk for wound-related bleeding complications in patients receiving anticoagulation.
Alejandro Gonzalez Della Valle, MD, attending orthopedic surgeon at Hospital for Special Surgery, and colleagues retrospectively reviewed data from 5,881 patients who underwent primary THA for osteoarthritis between 2016 and 2023 and received postoperative anticoagulation. Researchers divided patients into groups based on whether they received NSAIDs in addition to anticoagulation (n =

Eye care practitioners have a wealth of new information to inform their handling of dry eye disease with the third iteration of the Tear Film & Ocular Surface Society Dry Eye Workshop report.
“Everybody does dry eye differently,” Fiona Stapleton, FCOptom, PhD, FAAO, an author of the report and scientia professor at UNSW Sydney, told Healio. “This is about bringing the evidence together and presenting it in a way that is hopefully accessible, translatable and really helps clinicians to pick their way through the diagnosis and management.”
The Tear Film & Ocular Surface Society Dry Eye

AVD-104 yielded sustained vision improvements in patients with geographic atrophy, with no statistical difference reported in the rate of change in GA area vs. monthly avacincaptad pegol, according to a press release.
The phase 2a SIGLEC trial randomly assigned 300 patients with GA to treatment with an intravitreal dose of either 2 mg AVD-104 (Aviceda Therapeutics), a poly sialic acid-coated nanoparticle, every other month (100 patients), 1 mg AVD-104 monthly (100 patients) or 2 mg avacincaptad pegol (100 patients) for 24 months. Patients had an average age of 79 years and an average baseline

ORLANDO — In this video, Ann S. LaCasce, MD, MMSc, discusses highlights in mantle cell lymphoma presented at ASH Annual Meeting and Exposition.
Highlights included data on triplet therapies, which included Bruton tyrosine kinase inhibitors, BCL2 inhibitors and CD20 antibodies.
“All of these looked really good,” LaCasce, associate professor of medicine at Harvard Medical School and director of the Dana-Farber/Mass General Brigham fellowship in hematology/oncology, said. “I do think we’re going to need longer-term follow-up and randomized trials to really assess the long-term benefit.”

ORLANDO — In this video, Ann S. LaCasce, MD, MMSc, highlights preliminary results of a study of a chemotherapy-light triple combination regimen in older patients with diffuse large B-cell lymphoma.
The phase 2 trial, presented at ASH Annual Meeting and Exposition, evaluated R-Pola-Glo, which includes rituximab (Rituxan; Genentech, Biogen), polatuzumab vedotin (Polivy, Genentech) and glofitamab (Columvi, Genentech).
Preliminary data “looked very good,” LaCasce, associate professor of medicine at Harvard Medical School and director of the Dana-Farber/Mass General Brigham fellowship in

ORLANDO — In this video, Ann S. LaCasce, MD, MMSc, discusses results from the phase 3 EPCORE FL-1 trial, presented at ASH Annual Meeting and Exposition.
The randomized trial evaluated epcoritamab (Epkinly; Genmab, AbbVie) plus rituximab (Rituxan; Genentech, Biogen) and lenalidomide (Revlimid, Bristol Myers Squibb) compared with rituximab-lenalidomide alone in 488 patients with follicular lymphoma who had been treated with at least one previous line of systemic therapy.
A “significant benefit” was seen in the epcoritamab arm, said LaCasce, associate professor of medicine at Harvard Medical

ORLANDO — In this video, Jay S. Duker, MD, president and CEO of EyePoint Pharmaceuticals, discusses preclinical data on vorolanib presented at Eyecelerator@AAO.
“We’ve always known that vorolanib was a potent inhibitor of all the VEGF receptors,” Duker said. “What we’ve now discovered is we also have an anti-inflammatory component to vorolanib.”
Duker explained that “with this essentially bispecific approach of blocking both VEGF and inflammation, we are especially confident in the results of our clinical trial.”

ORLANDO — In this video from the American Academy of Ophthalmology meeting, Stephen J. Kim, MD, discusses the controversy surrounding FDA-approved treatments for geographic atrophy.
Two treatments are commercially available, but Kim, professor of ophthalmology at Vanderbilt Eye Institute, said the drugs are invasive and expensive, have side effects, and “don’t provide any meaningful visual function benefit.”
“They have some ability to modestly slow the rate of progression of the disease, but it hasn’t translated into any meaningful visual benefit that the patient can sense,” he said.

ORLANDO — In this video from the American Academy of Ophthalmology meeting, Stephen J. Kim, MD, discusses GLP-1 drugs and their retinal side effects.
GLP-1s can cause rapid progression of diabetic retinopathy, Kim said, and there are increasing concerns that they may cause nonarteritic anterior ischemic optic neuropathy.
“[GLP-1s] are widely used. They’re remarkable drugs. They transformed the landscape. The issue, though, is they have an increasing number of side effects,” Kim, professor of ophthalmology at Vanderbilt Eye Institute, said.

ORLANDO — In this video from the American Academy of Ophthalmology meeting, Stephen J. Kim, MD, discusses excitement about the use of AI in retina practices.
Possible applications of AI include rendering opinions on care and screening patients.
“Right now, I think the near-term application of this will be in reading images and helping to risk stratify patients based on risk of vision loss,” Kim, professor of ophthalmology at Vanderbilt Eye Institute, told Healio.